Patients with high MAGED2 protein expression had significantly shorter median OS (100.00 vs. 246.00 months; p < 0.001) and RFS (75.00 vs. 140.00 months; p = 0.0013) times in low-grade gliomas (Figure 4A,B); however, there was no significant difference in OS and RFS times in high-grade gliomas (p > 0.05; Figure 4C,D). Here, MAGED2 is linked to central nervous system cancer.